ReviewFrontiers in oncology2026
Intelligent therapeutic robotic-assisted surgery as the next frontier of precision oncology.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic-assisted surgery has evolved over the past two decades from mechanically assisted laparoscopy into an increasingly intelligent, biologically responsive therapeutic modality. While early robotic systems primarily enhanced dexterity and visualization, contemporary platforms now integrate artificial intelligence, advanced imaging, real-time biosensing, and pharmacological interfaces, extending surgical capability beyond physical manipulation alone. Robotic-assisted surgery is thus emerging at the intersection of digital intelligence and molecular medicine, with the potential to sense, interpret, and modulate tumor biology during operative intervention. However, current literature remains largely procedure-centered and mechanically focused, offering limited synthesis of how robotic systems converge with pharmacology, artificial intelligence, and systems medicine to actively regulate oncologic processes. A cohesive, oncology-oriented framework integrating intelligent robotics with intraoperative drug delivery and real-time biological feedback is notably lacking. This narrative review critically consolidates recent advances in pharmacologically enabled robotic platforms, AI-driven intraoperative cognition, and emerging closed-loop surgical-pharmacological architectures. It examines next-generation systems incorporating localized drug delivery, molecular diagnostics, and real-time pharmacodynamic monitoring, while discussing translational pathways and regulatory considerations shaping semi-autonomous oncologic ecosystems. By reframing robotic-assisted surgery as a dynamic therapeutic science rather than a purely mechanical tool, this review highlights a new frontier in precision oncology that has the potential to enable individualized, adaptive, and predictive cancer interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.